Doctors track Real-World results of Vision-Saving eye injections

NCT ID NCT04543331

Summary

This study observed how well an eye injection called brolucizumab worked in everyday medical practice for patients with two common causes of vision loss: 'wet' age-related macular degeneration (AMD) and diabetic macular edema (DME). It followed 572 patients in Germany for up to two years to see how the treatment reduced fluid in the retina and affected vision. The goal was to understand how the drug performs outside of strict clinical trials, using only data from routine doctor visits.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97070, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, 37075, Germany

  • Novartis Investigative Site

    Osnabrück, Lower Saxony, 49076, Germany

  • Novartis Investigative Site

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • Novartis Investigative Site

    Trier, Rhineland-Palatinate, 54296, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04103, Germany

  • Novartis Investigative Site

    Schneeberg, Saxony, 08289, Germany

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, 06118, Germany

  • Novartis Investigative Site

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    Aschersleben, 06449, Germany

  • Novartis Investigative Site

    Bayreuth, 95445, Germany

  • Novartis Investigative Site

    Berlin, 10713, Germany

  • Novartis Investigative Site

    Berlin, 14163, Germany

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    Breisach, 79206, Germany

  • Novartis Investigative Site

    Chemnitz, 09113, Germany

  • Novartis Investigative Site

    Cologne, 50968, Germany

  • Novartis Investigative Site

    Dresden, 01067, Germany

  • Novartis Investigative Site

    Dresden, 01324, Germany

  • Novartis Investigative Site

    Esslingen am Neckar, 73728, Germany

  • Novartis Investigative Site

    Glauchau, 08371, Germany

  • Novartis Investigative Site

    Homburg, 66421, Germany

  • Novartis Investigative Site

    Hösbach, 63768, Germany

  • Novartis Investigative Site

    Kiel, 24103, Germany

  • Novartis Investigative Site

    Leipzig, 04106, Germany

  • Novartis Investigative Site

    Magdeburg, 39104, Germany

  • Novartis Investigative Site

    Marienberg, 09496, Germany

  • Novartis Investigative Site

    Münster, 48145, Germany

  • Novartis Investigative Site

    Neubrandenburg, 17036, Germany

  • Novartis Investigative Site

    Neuburg am Inn, 86633, Germany

  • Novartis Investigative Site

    Saarbrücken, 66111, Germany

  • Novartis Investigative Site

    Schönebeck, 39218, Germany

  • Novartis Investigative Site

    Stralsund, 18435, Germany

  • Novartis Investigative Site

    Sulzbach, 66280, Germany

  • Novartis Investigative Site

    Torgau, 04860, Germany

  • Novartis Investigative Site

    Waren, 17192, Germany

  • Novartis Investigative Site

    Würzburg, 97080, Germany

Conditions

Explore the condition pages connected to this study.